Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally ...

The second time is not the charm for Replimune’s melanoma candidate RP1. | The second time is not the charm for Replimune’s ...

Artificial intelligence has long been seen as a way to supercharge drug development. | Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of ...

Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech ...

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...

A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...

Philips has issued a voluntary recall of software for its Trilogy Evo ventilator ser | Philips issued a voluntary recall of ...

Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune ...